In order to clarify this question, we evaluated in vitro and in vivo the effect of combining reactivation of p53 with MAPK inhibition on the efficacy of RT in BRAF-mutated melanoma with intrinsic and acquired resistance to BRAF inhibitors. This evidence concerns the gene TP53 and melanoma.